Methods, dosage regimens and compositions for treating hidradenitis
Patent Information
- Application Number
- CN202380028410.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-17
- Filing Date
- 2023-03-08
- Publication Date
- 2024-11-15
AI Technical Summary
[0007]因此,相当数量的(约40%)患有中度至重度HS的患者对用阿达木单抗的治疗没有反应,并且因此在患有中度至重度HS的患者中仍未满足对于有效、安全并且耐受良好的治疗的需求
[0013] The clinical benefit of treatment according to the present disclosure can be measured, for example, by the Hidradenitis Suppurativa Clinical Response Score (HiSCR).
Smart Images

Figure BDA0005047894710000161 
Figure BDA0005047894710000172 
Figure HDA0005047894720000011
Abstract
Description
Technical Field
[0001] The present disclosure provides methods, dosage regimens, and compositions for treating hidradenitis suppurativa. Background Art
[0002] Protein kinases are a family of enzymes that catalyze the phosphorylation of specific residues in proteins, which are broadly classified as tyrosine kinases and serine / threonine kinases. Inappropriate kinase activity caused by mutation, overexpression or inappropriate regulation, dysregulation or imbalance, and excessive or insufficient production of growth factors or cytokines is associated with many diseases, including but not limited to cancer, cardiovascular disease, allergies, asthma and other respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, metabolic disorders, and neurological and neurodegenerative disorders (such as Alzheimer's disease). Inappropriate kinase activity triggers a variety of biological cell responses related to cell growth, cell differentiation, cell function, survival, apoptosis, and cell migration that are involved in the aforementioned diseases and related diseases.
[0003] Therefore, protein kinases have become an important class of enzymes as targets for therapeutic intervention. Specifically, the JAK family of cellular protein tyrosine kinases (JAK1, JAK2, JAK3 and Tyk2) plays a central role in cytokine signaling (Kisseleva et al., Gene, 2002, 285, 1; Yamaoka et al. Genome Biology 2004, 5, 253). After binding to the receptor, cytokines activate JAK, which then phosphorylates the cytokine receptor, thereby generating docking sites for signaling molecules (particularly, members of the signal transducer and activator of transcription (STAT) family), ultimately leading to gene expression. Many cytokines are known to activate the JAK family. These cytokines include the interferon (IFN) family (IFN-α, IFN-β, IFN-ω, Limitin, IFN-γ, IL-10, IL-19, IL-20, IL-22), the gp130 family (IL-6, IL-11, OSM, LIF, CNTF, NNT-1 / BSF-3, G-CSF, CT-1, Leptin, IL-12, IL-23), the γC family (IL-2, IL-7, TSLP, IL-9, IL-15, IL-21, IL-4, IL-13), the IL-3 family (IL-3, IL-5, GM-CSF), the single chain family (EPO, GH, PRL, TPO), receptor tyrosine kinases (EGF, PDGF, CSF-1, HGF) and G protein-coupled receptors (AT1).
[0004] Hidradenitis suppurativa (HS) is a chronic, inflammatory, relapsing, debilitating skin disease that usually presents after puberty with painful, deep, inflamed lesions in the apocrine gland-bearing areas of the body. Zouboulis, C. et al., Dermatology, 231(2), pp.184-190 (2015). HS presents a variable clinical course. One of the cardinal features of the disease is the occurrence of intertrigo, but other areas of the skin may also be affected. In order of decreasing frequency, the affected areas are: groin, axilla, perineum and perianal area and in females, inframammary and / or intermammary folds, buttocks, mons pubis, scalp, retroauricular area and eyelids.
[0005] In Western Europe, the prevalence of self-reported disease is about 1%. The average interval from symptom onset to diagnosis is 7.2 years. Women are affected 2 to 5 times more frequently than men, and the disease may be more common in blacks than in whites. The severity of the disease ranges from mild (localized lesions) to severe (multiple areas of widely dispersed lesions, including interconnected sinus tracts and hypertrophic scars). Pain, drainage, and limited range of motion caused by scars may reduce quality of life. Jemec, GB, New Eng. J. Med., 366: 158-64 (2012); Kimball, A., et al., New Eng. J. Med., 375 (5), pp. 422-434 (2016).
[0006] Pain is a prominent feature of HS, which is reflected in a recently determined set of core outcomes to be evaluated in future trials. Thorlacius, L., et al., Brit. J. Derm., 179 (3), pp. 642-650 (2018). Most patients rated their pain according to the Numerical Rating Scale-11 (NRS11), ranging from 4 / 10-10 / 10, and described it at different times as burning, burning, pressure stretching, cutting, sharp, tight, splitting, gnawing, pressing, soreness, throbbing and pain. Currently, adalimumab is the only approved medical treatment for moderate to severe HS. It is based on two similarly designed (PIONEER I and PIONEER II) adalimumab phase 3 multicenter trials for HS. Kimball, A., et al., New Eng. J. Med., 375 (5), pp. 422-434 (2016). A total of 307 patients were enrolled in PIONEER I, and a total of 326 patients were enrolled in PIONEER II. The clinical response rate at week 12 [hidradenitis suppurativa clinical response (HiSCR): defined as a reduction of at least 50% from baseline in abscess and inflammatory nodule counts, with no increase in abscess or draining fistula counts] was significantly higher in the group receiving weekly adalimumab than in the placebo group: 41.8% vs. 26.0% in PIONEER I (P=0.003), and 58.9% vs. 27.6% in PIONEER II (P<0.001). Only in PIONEER II, at week 12, the improvement in the ordinal secondary outcomes (lesions, pain, and modified Sartorius score of disease severity) was significantly better in patients receiving adalimumab than in the placebo group. Kimball, A., et al., supra. The main difference between the study designs was that in PIONEER I, patients receiving oral antibiotic agents for HS were required to stop treatment at least 28 days before baseline; in PIONEER II, patients were allowed to continue treatment with a stable dose of antibiotics (tetracyclines).
[0007] Thus, a significant number (about 40%) of patients with moderate to severe HS do not respond to treatment with adalimumab, and thus there remains an unmet need for effective, safe, and well-tolerated treatments in patients with moderate to severe HS. Disclosed herein is the discovery that compounds and analogs that inhibit certain kinases (such as JAK1 and Tyk2) can be used to treat HS. Thus, methods for reducing the severity of HS symptoms in human subjects are described herein. These methods may include the step of administering to a subject a pharmaceutical composition comprising such a compound, which is effective in reducing the number and / or size of inflammatory lesions (e.g., nodules, abscesses, or draining fistulas), preventing their progression, alleviating pain caused thereby, or delaying further lesion development. Summary of the invention
[0008] The present disclosure provides a method for treating hidradenitis suppurativa in a subject to achieve reduced flares and increased HiSCR response levels.
[0009] The methods of the invention comprise administering to a subject in need thereof certain compounds disclosed herein that inhibit JAKs (such as, JAK1 and Tyk2) at a specific dose and / or in a specific method or treatment regimen.
[0010] In some embodiments, the present disclosure provides a method for treating hidradenitis suppurativa in a subject, the method comprising administering to a subject in need thereof a total of about 50 mg to about 300 mg per day, and preferably a total of about 100 mg to about 240 mg per day, of [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof, taken over a one-day period for about 16 weeks or longer.
[0011] In another aspect, the present disclosure provides a method for treating hidradenitis suppurativa in a subject, the method comprising administering to a subject in need thereof [(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone at a total dose of about 50 mg to about 300 mg per day, and preferably about 100 mg to about 240 mg per day, taken over a one-day period, for about 16 weeks or longer.
[0012] Other embodiments of the present disclosure include daily oral dosage regimens having the aforementioned compounds or pharmaceutically acceptable salts thereof in the disclosed daily amounts. Other embodiments are compositions having the aforementioned compounds or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
[0013] The clinical benefit of treatment according to the present disclosure can be measured, for example, by the Hidradenitis Suppurativa Clinical Response Score (HiSCR).
[0014] In some embodiments, the JAK inhibitor is effective in improving HiSCR.
[0015] Also provided is the use of a JAK inhibitor in the manufacture of a medicament for use in a method of treating and preventing hidradenitis suppurativa in a subject, as described herein. By way of example only, the present disclosure will be further understood from the description given below. Although the present disclosure is not limited thereto, an understanding of various aspects of the present disclosure will be gained through the following discussion and examples.
[0016] As used herein, "subject" refers to a mammal, companion animal, or livestock animal. Mammals include humans.
[0017] The term "companion animal" refers to an animal that is kept as a pet or domestic animal. Examples of companion animals include dogs, cats and rodents (including hamsters, guinea pigs, gerbils, etc.), rabbits, ferrets and birds.
[0018] The term "livestock" refers to animals that are raised or fed in an agricultural environment to produce products such as food or fiber or for labor. In some embodiments, livestock are suitable for consumption by mammals (e.g., humans). Examples of livestock include cattle, goats, horses, pigs, sheep (including lambs), and rabbits, as well as poultry, such as chickens, ducks, and turkeys.
[0019] The term "treatment" means to relieve the symptoms associated with a disease, disorder or condition, or to prevent further development or worsening of these symptoms. Depending on the patient's disease and condition, the term "treatment" as used herein may include one or more of curative treatment, palliative treatment and preventive treatment. Treatment may also include the administration of a pharmaceutical formulation of the present disclosure in combination with other therapies.
[0020] The term "therapeutically effective" indicates the ability of an agent to prevent or improve the severity of a disease while avoiding the adverse side effects typically associated with alternative therapies. The phrase "therapeutically effective" should be understood to be equivalent to the phrase "effective for treatment, prevention or improvement," and both are intended to define the amount of each agent used in the combination therapy so that the purpose of improving the severity of the disease, or pain or other symptoms and frequency of occurrence, compared to treatment with each agent alone will be achieved while avoiding the adverse side effects typically associated with alternative therapies.
[0021] "Pharmaceutically acceptable" means suitable for use in a "subject." BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Embodiments of the present disclosure are described herein with reference to the following drawings.
[0023] Figure 1 Schematic diagram of the method for the studies performed in Example 9.
[0024] Figure 2 is a graph depicting the HiSCR response of Example 9 compared to placebo.
[0025] Figure 3 Forest plots of several clinical variables for Example 9 compared to placebo.
[0026] Figure 4 Collection of bar graphs of Week 16 HISCR response by baseline Hurley staging for Example 9 compared to placebo.
[0027] Figure 5 This is the Kaplan Meier curve of the first outbreak time (FAS) of Example 9. DETAILED DESCRIPTION
[0028] The present disclosure relates to a method for treating hidradenitis suppurativa in a subject, the method comprising administering to a subject in need thereof a compound that inhibits certain JAKs, such as JAK1 and Tyk2. The present disclosure also provides pharmaceutical compositions comprising such inhibitors. Thus, the present disclosure provides a method for treating hidradenitis suppurativa in a subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to a subject in need thereof a compound [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof. The present disclosure also provides the method, wherein the salt is a p-toluenesulfonate salt.
[0029] The present disclosure also provides the method, wherein the compound is [(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof.
[0030] The present disclosure also provides the method, wherein the subject's HiSCR is improved after administration of the compound.
[0031] The present disclosure also provides the method, wherein after administration of the pharmaceutical composition, the median size of the hidradenitis suppurativa lesions in the subject is reduced.
[0032] The present disclosure also provides such methods, wherein following administration of the compound, the subject experiences reduced pain associated with hidradenitis suppurativa lesions.
[0033] The present disclosure also provides the method, wherein after administration of the compound, the time to appearance of new hidradenitis suppurativa lesions in the subject is increased.
[0034] The present disclosure also provides the method, wherein the subject has a reduced incidence of flare-ups.
[0035] The present disclosure also provides a pharmaceutical composition or a veterinary composition, comprising any compound or a pharmaceutically acceptable salt thereof as described above and a pharmaceutically acceptable carrier, wherein the composition is used in treating and preventing hidradenitis suppurativa.
[0036] The present disclosure also provides a method for treating hidradenitis suppurativa in a subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject in need thereof an amount of a compound that inhibits JAKs, including JAK1 and Tyk2, effective to treat the symptoms of hidradenitis suppurativa in the subject.
[0037] The present disclosure also provides the method, wherein the effective amount is about 0.01 to about 100 mg / kg body weight / day, or more preferably about 0.1 to about 10.0 mg / kg body weight / day, in a single dose or in divided doses administered two, three or four times a day.
[0038] The present disclosure also provides a method for treating hidradenitis suppurativa in a subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to a subject in need thereof an amount of [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof effective to treat the symptoms of hidradenitis suppurativa in the subject.
[0039] The present disclosure also provides the method, wherein the effective amount is about 0.01 to about 100 mg / kg body weight / day, or more preferably about 0.1 to about 10.0 mg / kg body weight / day, in a single dose or in divided doses administered twice, three times or four times a day. The present disclosure also provides the method, wherein the effective amount is about 45 mg, QD administration.
[0040] The present disclosure also provides the method, wherein the salt is p-toluenesulfonate.
[0041] The present disclosure also provides the method, wherein the effective amount is about 0.01 to about 100 mg / kg body weight / day, or more preferably about 0.1 to about 10.0 mg / kg body weight / day, in a single dose or in divided doses administered twice, three times or four times a day. The present disclosure also provides the method, wherein the effective amount is about 400 mg, QD administration.
[0042] In therapeutic uses for treating a condition in a mammal, the compounds of the present disclosure or pharmaceutical compositions thereof may be administered orally, parenterally, topically, rectally, transmucosally or enterally. Parenteral administration includes indirect injection to produce a systemic effect or direct injection into the affected area. Topical administration includes treatment of the skin or organs readily accessible by topical application, such as the eyes or ears. Transdermal delivery is also included to produce a systemic effect. Rectal administration includes the form of suppositories. Preferred routes of administration are oral, topical and parenteral.
[0043] The pharmaceutical compositions of the present disclosure can be manufactured by methods well known in the art, for example, by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing process or spray-drying.
[0044] The pharmaceutical composition used according to the present disclosure can be prepared in a conventional manner using one or more pharmaceutically acceptable carriers (including excipients and adjuvants), which is conducive to processing the active compound into a preparation that can be used pharmaceutically. Suitable formulations depend on the selected route of administration. Pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art, and are therefore included in the present disclosure. Such excipients and carriers are described in, for example, Remington's Pharmaceutical Sciences, Mack Pub. Co., New Jersey (1991). The preparations disclosed herein can be designed to be short-acting, quick-release, long-acting, and sustained-release. Therefore, the pharmaceutical preparation can also be formulated for controlled release or slow release.
[0045] Pharmaceutical compositions suitable for use in the present disclosure include compositions wherein the active ingredient is contained in an amount sufficient to achieve the intended purpose (i.e., control or treatment of HS). More specifically, a therapeutically effective amount means an amount of a compound that is effective in preventing, alleviating or ameliorating symptoms / signs of a disease or prolonging the survival of a treated subject.
[0046] The amount of active ingredient (i.e., compound of the present disclosure) in pharmaceutical compositions and unit dosage forms thereof can vary or be adjusted widely according to the mode of administration, the potency of the specific compound, and the desired concentration. In general, the amount of the active ingredient will range from 0.01% to 99% by weight of the composition.
[0047] In general, the therapeutically effective amount of the active ingredient dosage ranges from about 0.01 to about 100 mg / kg body weight / day, preferably from about 0.1 to about 10 mg / kg body weight / day, more preferably from about 0.3 to 3 mg / kg body weight / day, and even more preferably from about 0.3 to 1.5 mg / kg body weight / day. It should be understood that the dosage can vary according to the needs of each subject and the severity of the disorder or disease being treated.
[0048] The desired dose may conveniently be presented in a single dose, or as divided doses to be administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, for example, into a number of discrete, loosely spaced administrations; such as multiple inhalations from an insufflator or by applying a plurality of drops to the eye.
[0049] In addition, it should be understood that in order to quickly reach the required plasma concentration, the initial dose administered can be increased to exceed the upper limit above. On the other hand, the initial dose can be less than the optimal dose, and the daily dose can be gradually increased during the course of treatment according to the specific circumstances. If necessary, the daily dose can also be divided into multiple doses for administration, for example, twice to four times a day.
[0050] In a preferred embodiment, lesions of hidradenitis suppurativa are treated by administering the compound [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone (also known as brepocitinib or PF-06700841) or a pharmaceutically acceptable salt thereof to a human subject or patient in need thereof. The compound is administered in a dosage of about 50 mg to about 300 mg per day, and preferably about 100 mg to about 240 mg per day, taken over a one-day period, for about 16 weeks or longer. A particularly preferred dosage is about 25 mg to about 100 mg four times a day for about 16 weeks or longer. The most preferred dosage is about 45 mg four times a day for about 16 weeks or longer. The amount administered is preferably effective to achieve a HiSCR response of ≥50% in a Hurley 2 subject or patient within 16 weeks after the start of administration. The amount administered is preferably effective to achieve a HiSCR response of ≥30% in a Hurley 3 subject or patient within 16 weeks after the start of administration. The amount administered is preferably effective to achieve a flare probability of ≤20% in a subject or patient up to 16 weeks after the start of administration. Oral administration is preferred.
[0051] In particular, in the treatment of diseases, suitable agents for use in combination therapy with the compounds described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compounds or salts include: 5-lipoxygenase activating protein (FLAP) antagonists; leukotriene antagonists (LTRAs), such as LTB4, LTC4, LTD4, LTE4, CysLT1 or CysLT2, for example, montelukast or zafirlukast; histamine receptor antagonists, such as histamine type 1 receptor antagonists or histamine type 2 receptor antagonists, for example, loratadine, fexofenadine, desloratadine, levocetirizine, methapyrilene or cetirizine; α1-adrenoceptor agonists or α2-adrenoceptor agonists, for example, phenylephrine, methoxamine, oxymetazoline or methyl norepinephrine (methyl norephrine); muscarinic M3 receptor antagonists, such as tiotropium or ipratropium; dual muscarinic M3 receptor antagonists / β2 agonists; PDE inhibitors, such as PDE3 inhibitors, PDE4 inhibitors, or PDE5 inhibitors, such as theophylline, sildenafil, vardenafil, tadalafil, ibudilast, cilomilast, or roflumilast; sodium cromoglycate or nedocromil sodium; cyclooxygenase (COX) inhibitors , such as non-selective inhibitors (e.g., aspirin or ibuprofen) or selective inhibitors (e.g., celecoxib or valdecoxib); glucocorticoids, such as fluticasone, mometasone, dexamethasone, prednisolone, budesonide, ciclesonide ) or beclamethasone; anti-inflammatory monoclonal antibodies, such as infliximab, adalimumab, tanezumab, ranibizumab, bevacizumab or mepolizumab; beta2 agonists, such as salmeterol, albuterol, salbutamol, fenoterol or formoterol, particularly long-acting beta2 agonists; integrin antagonists, such as natalizumab; adhesion molecule inhibitors, such as VLA-4 antagonists; kinin B1 or B2 receptor antagonists; immunosuppressants, such as IgE pathway inhibitors (e.g., omalizumab) or cyclosporine;Matrix metalloproteinase (MMP) inhibitors, such as MMP-9 or MMP-12 inhibitors; tachykinin NK1, NK2 or NK3 receptor antagonists; protease inhibitors, such as elastase, chymotrypsin or cathepsin G inhibitors; adenosine A; 2a Adenosine A receptor agonist 2b receptor antagonists; urokinase inhibitors; dopamine receptor agonists (e.g., ropinirole), in particular dopamine D2 receptor agonists (e.g., bromocriptine); NFκB pathway modulators, such as IKK inhibitors; another modulator of the cytokine signaling pathway, such as syk kinase, p38 kinase, SPHK-1 kinase, Rho kinase, EGF-R or MK-2 inhibitors; mucolytics, mucokinetics or antitussives; antibiotics; antivirals; vaccines; chemokines; epithelial sodium channel (ENaC) blockers or epithelial sodium channel (ENaC) inhibitors; nucleotide receptor agonists, such as P2Y2 agonists; thromboxane inhibitors; niacin; 5-lipoxygenase (5-LO) inhibitors, for example, zileuton uton); adhesion factors such as VLAM, ICAM or ELAM; CRTH2 receptor (DP2) antagonists; prostaglandin D2 receptor (DP1) antagonists; hematopoietic prostaglandin D2 synthase (HPGDS) inhibitors; interferon-β; soluble human TNF receptors, such as Etanercept; HDAC inhibitors; phosphoinositotide 3-kinase γ (PI3Kγ) inhibitors; phosphoinositol 3-kinase δ (PI3Kδ) inhibitors; CXCR-1 or CXCR-2 receptor antagonists; IRAK-4 inhibitors; and TLR-4 or TLR-9 inhibitors, including pharmaceutically acceptable salts of specifically named compounds and pharmaceutically acceptable solvates of the specifically named compounds and salts.
[0052] Pharmaceutically acceptable excipients may include, but are not limited to, binders, lubricants, glidants, inert diluents, preservatives, disintegrants, and dispersants. Tablets and other solid dosage forms, such as but not limited to capsules, pills, powders, and granules, may include coatings, such as enteric coatings.
[0053] Chemical synthesis
[0054] The compounds of the present disclosure can be prepared by any method known in the art. Specifically, the compounds of the present disclosure can be prepared by referring to the procedures described in the prior art references, where the procedures are disclosed.
[0055] For those compounds that specifically inhibit Tyk2 and JAK1, including [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone, the preparation method has been disclosed in U.S. Patent No. 9,663,526, the contents of which are incorporated herein in their entirety.
[0056] The contents of U.S. Provisional Application No. 62 / 899,133, filed on September 11, 2019, cited in PCT Publication No. 2021 / 048736, are incorporated herein in their entirety.
[0057] Example
[0058] The following non-limiting examples are presented merely to illustrate the present disclosure. Those skilled in the art will appreciate that there are numerous equivalents and variations that are not illustrated, but which still form part of the teachings of the present invention.
[0059] Example 1
[0060] Hidradenitis suppurativa clinical response (HiSCR)
[0061] This study provides information on the efficacy, safety, tolerability, and pharmacokinetics of therapeutic agents examined in the oral treatment of moderate to severe HS. The maximum duration of this study is approximately 26 weeks. This includes a screening period of up to 6 weeks, a dosing period of 16 weeks, and a follow-up period of 4 weeks. The study enrolled a total of approximately 192 participants (expected to provide approximately 156 completers). After the screening period, participants who met the eligibility criteria at the baseline visit were randomly assigned to receive 1 of 6 treatments. One oral dose level of each therapeutic agent (one of which was [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone (45mg QD)) or matching placebo was studied at a ratio of 3:1. For the analysis, placebos were combined to give a final treatment:placebo ratio of 1:1:1:1 for each treatment and pooled placebo. No more than 30% of the enrolled participants were anti-TNF inadequate responders. Participants were stratified based on whether they were anti-TNF inadequate responders.
[0062] In addition, no more than 20% of enrolled participants entered the study on a background of concomitant oral antibiotic therapy for the treatment of HS; the dosing regimen (dose and frequency) must have been stable for at least 8 weeks (56 days) prior to the baseline (Day 1) visit and remained stable throughout study participation. Antibiotics taken on an “as needed” (PRN) basis were not considered stable doses. Participants were stratified based on whether they were on a background of concomitant antibiotic therapy. The chronic toxicology package for each asset supported a planned study treatment duration of 16 weeks. Clinical response of hidradenitis suppurativa was the primary endpoint used, defined as:
[0063] Relative to baseline, total abscess and inflammatory nodule (AN) counts were reduced by at least 50%, with no increase in abscess counts and no increase in draining fistula counts.
[0064] Example 2
[0065] Lesion count
[0066] The number and physical location (right / left axillary, right / left inframammary, intermammary, right / left buttocks, right / left inguinal-femoral folds, perianal, perineal, other) of inflammatory and noninflammatory nodules, abscesses, draining and nondraining fistulas, and hypertrophic scars were assessed according to standards in the field.
[0067] Example 3
[0068] Abscess count
[0069] The number of abscesses (fluctuating, with or without drainage, tenderness or pain) in each area as defined above was counted.
[0070] Example 4
[0071] Inflammatory nodule count
[0072] The number of inflammatory nodules (tenderness, erythema, pyogranulomatous lesions) in each area as defined above was counted.
[0073] Example 5
[0074] Fistula count
[0075] The number of fistulas (sinus tracts communicating with the skin surface and draining purulent fluid) in each area as defined above was counted.
[0076] Example 6
[0077] Hurley Staging
[0078] The Hurley stages are defined as follows:
[0079] Stage I: Abscess formation, single or multiple, without sinus tracts and scarring.
[0080] Stage II: One or more widely separated recurrent abscesses with sinus tract formation and scarring (scarring)
[0081] Stage III: Multiple interconnected sinus tracts and abscesses throughout the area, with diffuse or near-diffuse involvement.
[0082] Hurley staging is performed according to the standards in the field.
[0083] Example 7
[0084] Modified Sartorius scale
[0085] The modified Sartorius score was calculated by counting lesions in the following 12 anatomical regions: left axilla, right axilla, left inframammary region, right inframammary region, intermammary region, left buttock, right buttock, left inguinal-crural fold, right inguinal-crural fold, perianal region, perineal region, other. For each anatomical region, the regional Sartorius score was calculated as follows:
[0086] Involved anatomical regions: 3 points for each involved region (ie, any lesion count in this anatomical region > 0; otherwise, 0 points).
[0087] The number and scoring of lesions (abscesses, nodules, fistulas, scars) were: 2 points for each nodule (inflammatory and non-inflammatory), 4 points for each abscess, 4 points for each fistula (draining and non-draining), 1 point for each hypertrophic scar, and 1 point for each “other”.
[0088] The longest distance between 2 relative lesions (ie, 0 if there is no active lesion; 2 if the longest distance or size between 2 relative lesions is <50 mm; 4 if the longest distance or size between 2 relative lesions is ≥50 mm and <100 mm; 6 if the longest distance or size between 2 relative lesions is ≥100 mm).
[0089] In each area, the lesions were clearly separated by normal-appearing skin: if all lesions were clearly separated by normal-appearing skin, it was scored 0; otherwise, it was scored 6.
[0090] The modified Sartorius Total Score is the sum of all 12 regional scores.
[0091] Example 8
[0092] Erythema Assessment
[0093] The overall degree of erythema in each HS-affected anatomical area was assessed using a four point ordinal scale ranging from 0 (no redness), 1 (faint but recognizable pink), 2 (moderate redness), or 3 (very red or bright red).
[0094] Example 9 and Comparative Example 1
[0095] summary
[0096] The above example is a phase 2A double-blind parallel group study evaluating the efficacy of PF-06700841, a dual inhibitor of human tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), compared to placebo in patients with moderate to severe hidradenitis suppurativa (HS). PF-06700841 met the predefined primary efficacy criteria (multiple adjusted p-value <0.1).
[0097] The tests performed on PF-06700841 constitute Example 9. PF-06700841 refers to brepocitinib, (1S)-2,2-difluorocyclopropyl[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone.
[0098] The test performed with the placebo constitutes Comparative Example 1.
[0099] For PF-06700841, at Week 16, the placebo-adjusted HiSCR rate percentage (50% reduction in abscess and inflammatory nodule (AN) counts from baseline, with no increase in abscess and draining fistula counts from baseline) was 18.7 (p=0.0298). Relative to the primary endpoint HiSCR response rate at Week 16, the response rate in the PF-06700841 group (together with the placebo group) was relatively high in participants with moderate HS (Hurley stage II at baseline). A statistically significant reduction from placebo was observed in the PF-06700841 (δ=-22.3ρ=0.006) group in the percentage of participants who experienced at least one flare (defined as an increase of at least 25% in AN counts, with a minimum increase of 2 from baseline) until Week 16. Pain is an important symptom for participants with HS. For the percentage of NRS30 responders (≥30% reduction from baseline and ≥1 unit reduction in the PGA-Skin Pain Numeric Rating Scale (NRS30) at worst) in participants with a baseline score of ≥3 at Week 16, the difference between PF-06700841 and placebo was 6.5 (p=0.265). Overall consistent and robust efficacy was observed in the primary and secondary endpoints of PF-06700841. PF-06700841 appears to be generally safe and well tolerated. Most of the reported treatment-emergent adverse events (TEAEs) were mild and moderate. There were no deaths or cases of herpes zoster / herpes simplex in the study. Based on preliminary population PK analysis, the expected exposure in HS appears to be achieved compared to healthy populations or other patient populations of the compound.
[0100] Test Design
[0101] This was a randomized, double-blind, parallel-group, multicenter study that enrolled approximately 192 participants with moderate to severe HS (approximately 156 completers). Participants were randomized in a 3:1 ratio to PF-06700841 (along with two other treatments studied concurrently) and matching placebo. Each randomized participant was followed for a 16-week dosing period and a 4-week follow-up period. For analysis, the placebo groups were combined to give a 1:1:1:1 ratio for each treatment and pooled placebo. No more than 30% of participants were enrolled with an inadequate anti-TNF response, and no more than 20% of participants were on a background of antibiotic therapy, and a stratified randomization strategy was adopted for this study. Efficacy data for all randomized participants up to Week 16 are within the scope of this report.
[0102] Primary Objective and Primary End Points
[0103] The primary objective of the study was to evaluate the efficacy and safety of PF-06700841 relative to placebo in participants with HS. The primary efficacy endpoint was the percentage of participants with a HiSCR response (50% reduction from baseline in abscess and inflammatory nodule (AN) counts, with no increase from baseline in abscess and draining fistula counts) at Week 16.
[0104] Secondary Objectives and End Points
[0105] - Percentage of participants experiencing at least one flare event (defined as an increase of at least 25% in AN counts, with a minimum increase of 2 from baseline after Week 4) by Week 16.
[0106] The percentage of participants achieving a total AN count of 0, 1, or 2 at Week 16.
[0107] Among participants with a baseline NRS ≥3, the percentage of participants who achieved a ≥30% reduction from baseline and a ≥1 unit reduction in the PGA-Skin Pain Numeric Rating Scale (NRS30) at Week 16 at its worst.
[0108] - Percent change from baseline in the International Hidradenitis Suppurativa Severity Scoring System (IHS4) at Week 16. This IHS4 score is a weighted scoring system and is calculated as follows: number of nodules multiplied by 1 + number of abscesses multiplied by 2 + number of drainage tracts (fistulas / sinuses) multiplied by 4. Mild HS is defined as an IHS4 score of 11.
[0109] The primary and secondary efficacy analyses were performed using data from all participants, but treatment effects were also assessed in participants with varying degrees of disease severity based on baseline Hurley stage. The study population consisted of 67% of participants with stage II (recurrent abscesses with tract formation and scarring, single or multiple, lesions widely separated) and 33% of participants with stage III (multiple interconnecting tracts and abscesses throughout the region with diffuse or near-diffuse involvement).
[0110] The safety and tolerability of PF-06700841 over time were evaluated using the incidence of treatment-emergent adverse events (TEAEs), vital signs, and specific clinical laboratory abnormalities including but not limited to hemoglobin, neutrophils, platelets, lymphocytes, lipids, eGFR, liver function tests (LFTs), and CPK.
[0111] Analysis population and methods
[0112] All participants who received at least one dose of randomized study drug and had a baseline were included in the full analysis set (FAS), the population for efficacy analysis. The safety analysis set (SAS) includes all participants who received at least one dose of the study product. After treating missing data as non-responders, the Cochran Mantel Hanzel (CMH) test was used to analyze the HiSCR response data at week 16 comparing the active treatment group and the placebo group with a minimum risk (MR) weight strategy, adjusted for stratification factors of previous anti-TNF failure status. Due to the very small number of participants with concomitant antibiotic use at baseline in some subgroups, it was not included in the model as a stratum factor. Hochberg's step-up procedure was used to resolve any multiplicity generated by the analysis of 3 different treatments in the same study, and the overall family error rate was controlled at a level of 0.1. All continuous secondary endpoints were analyzed using an ANCOVA model, in which missing observations were filled using a multiple imputation (MI) method.
[0113] Pharmacokinetics
[0114] Blood was collected for PK samples prior to dosing, at Weeks 1, 2, 4, 6, 8, and 16, and at 0.5, 1, 2, and 4 hours post-dose at Week 8. Population PK modeling was used to analyze the available data.
[0115] Participant Population, Baseline, and Disease Characteristics
[0116] 359 participants (67% moderate and 33% severe) were screened, and HS participants from more than 60 sites in 3 countries (United States, Canada, and Australia) were enrolled in the study. The data of these moderate to severe participants were included in the efficacy analysis set (FAS) and the safety analysis set (SAS). The demographic and baseline characteristics of the patients (Table 1) were similar and generally well balanced. The mean total AN count baseline score for the treated participants was 13 (SD=10.9). Most (77.8%) of the participants were female. The mean total AN count for PF-06700841 was 12 (SD=10.0). At baseline, there were participants with insufficient anti-TNF response, and the participants were on a background of concomitant oral antibiotic therapy. The treatment groups appeared comparable in age, sex, total AN count, fistula count, IHS4 score, and baseline pain score.
[0117] Figure 2The graph depicts the HiSCR response of Example 9 relative to placebo. The graph shows the estimated values and 90% confidence intervals (CI) of the percentage of participants with HiSCR response over time [placebo (red), PF-06700841 (yellow)]. The yellow graph shows that the response was the highest at week 16. The red graph shows that the response was the lowest at week 16.
[0118] Figure 3 Forest plot of AN counts relative to placebo for Example 9. Forest plot of estimates of the difference (90% CI) at Week 16 compared to placebo, PF-06700841 (yellow) for the percentage of participants experiencing at least one flare event, AN counts at 0, 1, or 2, NRS-30 (30% reduction in average weekly pain score with a baseline score of at least 3), and percent change from baseline in IHS4 score at Week 16.
[0119] Figure 4 Collection of bar graphs of Week 16 HiSCR responses by baseline Hurley staging relative to placebo for Example 9. The percentage of participants achieving a Week 16 HiSCR response by baseline Hurley staging (FAS, NRI) is shown.
[0120] Figure 5 Kaplan Meier plots comparing the time to first flare (FAS) for each of placebo (red) and PF-06700841 (yellow). The placebo plot depicts the highest probability of flare at week 16. The PF-06700841 plot depicts the lowest probability of flare at week 16.
[0121] Table 1
[0122] Baseline and disease characteristics
[0123]
[0124]
[0125] effect
[0126] PF-06700841 met the pre-specified efficacy criteria for the primary endpoint. The stratified CMH test estimate of the difference from placebo in the HiSCR response rate (90% CI) at Week 16 was 18.7 [90% CI = (2.7, 34.6)]. The results of the sensitivity analysis (non-stratified analysis using the exact method of Chan and Zhang (1999)) were similar to the primary analysis.
[0127] Table 2
[0128] Percentage of Participants Achieving Week 16 HiSCR Response (FAS, NRI)
[0129]
[0130] For all three compounds, no statistical separation of HiSCR response rates from placebo was observed through Week 12 ( Figure 1 Participants with moderate disease severity at baseline (Hurley stage II) had higher response rates compared with those with severe HS (Hurley stage III at baseline) across all three active treatments and with placebo. Numerically higher response rates to the primary endpoint at Week 16 were observed in Hurley stage II participants (HiSCR response rate = 59.4%) compared with Hurley stage III participants (40%) and the overall population treated with PF-06700841 (51.9%). Figure 4 ).
[0131] exist Figure 3 Results for the secondary endpoints of PF-06700841 are provided in:
[0132] 1. The percentage of participants who achieved at least one flare event by week 16;
[0133] 2. The percentage of participants who achieved a total AN count of 0, 1, or 2 at Week 16;
[0134] 3. The percentage of participants who achieved an NRS 30 response; and
[0135] 4. Percent change from baseline in IHS4 at Week 16.
[0136] Flare events (defined as an increase in AN count of at least 25%, with a minimum increase of 25% from baseline) were a pre-specified secondary endpoint of this study, and a statistically significant reduction in the flare event rate (at least one flare event before Week 16) was observed with the PF-06700841 (δ=-22.3, p=0.006) treatment group. Figure 5 As shown, the time to the first outbreak in the treatment group was significantly reduced. The Cox proportional model estimated that the hazard ratio for the time to the first outbreak of PF-06700841 was 0.4. In this study, a clinically significant reduction in AN counts was demonstrated by achieving AN counts of 0, 1, or 2 at the end of 16 weeks of treatment. Compared with placebo (p=0.046), more participants (15.6%) in the PF-06700841 treatment group achieved total AN counts of 0, 1, or 2 at week 16.
[0137] Worst skin pain and mean skin pain due to HS were assessed using the patient's global assessment of the Skin Pain Numeric Rating Scale (NRS). Participants completed the assessment in a diary before going to bed and responded to items based on a recall period of the past 24 hours. A large amount of data (%) related to this endpoint was missing. Missing data were imputed using the LOCF (last observation carried forward) method. Regarding the Skin Pain NRS30 at Week 16, all compounds did not differ from placebo ( Figure 2 ). The difference in skin pain NRS30 at week 16 for PF-06700841 compared to placebo was 6.5 (p=0.265). The results for other patient-reported outcome endpoints, such as the change from baseline over time in the Dermatology Life Quality Index (DLQI) and the change from baseline over time in each domain of the Short Form Health Survey, version 2, Acute (SF36v2 Acute), were consistent with the other endpoints. In the PF-06700841 treatment group, the difference from placebo in the percentage change from baseline in the IHS4 score at week 16 was -14.6 (p=0.145).
[0138] It should be understood that the foregoing description only illustrates the present disclosure. Those skilled in the art may design various alternatives and modifications without departing from the present disclosure. Therefore, the present disclosure is intended to cover all such alternatives, modifications and variations that fall within the scope of the appended claims.
Claims
1. A method for treating hidradenitis suppurativa in a human subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject in need thereof the compound [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof, wherein the compound is administered in a dose of about 50 mg to about 300 mg total per day taken over a one-day period.
2. A method for treating hidradenitis suppurativa in a human subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject in need thereof the compound [(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof, wherein the compound is administered in a dose of about 50 mg to about 300 mg total per day taken over a one-day period.
3. The method of claim 1 or 2, wherein the salt is p-toluenesulfonate.
4. The method of claim 1 or 2, wherein the compound is administered in a dose of about 100 mg to about 240 mg total taken over a one-day period.
5. The method of claim 1 or 2, wherein the compound is administered at a dose of about 25 mg to about 100 mg four times a day.
6. The method of claim 1 or 2, wherein the compound is administered at a dose of about 45 mg four times a day.
7. The method of any one of claims 1 to 6, wherein the subject is a Hurley 2 subject, wherein the subject achieves a HiSCR response of ≥ 50% within 16 weeks of initiation of administration.
8. The method of any one of claims 1 to 6, wherein the subject is a Hurley 3 subject, wherein the subject achieves a HiSCR response of ≥ 30% within 16 weeks of initiation of administration.
9. The method of any one of claims 1 to 6, wherein the subject has a flare probability of ≤ 20% within a maximum of 16 weeks after initiation of administration.
10. The method of any one of claims 1 to 6, wherein the treatment reduces inflammatory nodules, abscesses, and draining fistulas as measured by the subject's HiSCR score.
11. The method of any one of claims 1 to 6, wherein the treatment reduces the median size of hidradenitis suppurativa lesions in the subject.
12. The method of any one of claims 1 to 6, wherein the treatment reduces the subject's pain associated with the subject's hidradenitis suppurativa lesions.
13. The method of any one of claims 1 to 6, wherein the treatment increases the time to development of new hidradenitis suppurativa lesions in the subject.
14. The method of any one of claims 1 to 6, wherein the administration is in a single dose or in divided doses administered two, three or four times daily.
15. A daily dosage regimen for treating hidradenitis suppurativa in a subject having lesions associated with hidradenitis suppurativa, wherein the compound is [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof, wherein the compound is present in the dosage regimen at about 50 mg to about 300 mg.
16. A daily dosage regimen for treating hidradenitis suppurativa in a subject having lesions associated with hidradenitis suppurativa, wherein the compound is [(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof, wherein the compound is present in the dosage regimen in a total of about 50 mg to 300 mg per day taken over a one-day period.
17. A composition for treating hidradenitis suppurativa in a subject having lesions associated with hidradenitis suppurativa, wherein the composition comprises an amount of the compound [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
18. A composition for treating hidradenitis suppurativa in a subject having lesions associated with hidradenitis suppurativa, wherein the composition comprises an amount of the compound [(1R)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
